Share on Pinterest

Can a common vitamin B5 supplement help treat psoriasis? A new study shows potential. Guido Mieth/Moment/Getty Images
  • A new study in mice and humans suggests that a form of vitamin B5 may help reduce psoriasis plaques and symptoms.
  • Researchers observed that supplementing with panthethine and blocking vanin enzymes helped regulate inflammation and immune cells involved in psoriasis in human trials within 12 weeks.
  • The study helps solidify psoriasis’ categorization as an immune and metabolic disorder and identifies a functional metabolic link between psoriasis flare-ups, panthethine, and cholesterol regulation.
  • However, experts caution against using standard vitamin B5 supplements to treat psoriasis, noting that the derivative used in the trials differs from store-bought versions and has not been proven to help.

A new study published in the Journal of Experimental Medicine suggests that pantethine, a derivative of vitamin B5, may help calm immune cells involved in psoriasis and be an effective add-on treatment.

As part of the study, scientists conducted a small human trial and ran experiments in mice. In these trials, researchers identified a biological “off-switch” for overactive immune cells in psoriasis—and found that pantethine can flip that switch.

In the human trial, involving 24 participants and lasting 12 weeks, all patients used standard topical therapy of a combination of a vitamin D analog and a topical steroid (calcipotriene/betamethasone). Half of the participants also took 600 mg of panthethine twice daily as an add-on treatment.

The current standard of care and treatment for psoriasis includes topical steroids, vitamin D analogs, and a class of medication called biologics.

The researchers saw greater improvement in psoriasis symptoms in the group that took pantethine.

They also observed similar results in experiments with mice. They saw that blocking the Vanin enzyme prevented psoriasis from taking hold, and panthethine supplements actively reversed skin plaques and inflammation.

“We’ve known for a long time that psoriasis is driven by the immune system, especially the immune cells that kick off the inflammation, which many of our biologic injections are designed to calm,” said Christina Marcelus, MD, MS, FAAD, board certified dermatologist, who was not involved in the study.

How panthethine calms down inflammation in psoriasis

Prior research has shown that a specific type of immune cell (CCR7+ dendritic cells) triggers psoriasis flare-ups by producing inflammatory proteins (IL-23), which connects this cellular energy/metabolic pathway directly to known causes of the disease.

In the experiments, the researchers observed in mice that the Vanin enzyme causes panthethine to be depleted, which then led to a rise in internal cholesterol levels. This then led to dendritic cell overactivationwhich heightened psoriasis inflammation.

After supplementing with pantethine, the researchers saw that pantethine helped restore balance and quiet overactive dendritic cells in mice and humans.

“What’s new here is the metabolic piece. This study suggests that how those immune cells handle cholesterol helps decide how inflammatory they become, and that a compound called panthethine, a form of vitamin B5, helps keep that in check,” Marcelus said.

“What makes this (study) interesting is that it connects the way immune cells process fats with the inflammation driving psoriasis. It suggests we may eventually be able to control certain inflammatory pathways by targeting cellular metabolism, rather than focusing exclusively on inflammatory proteins,” Shamsa Kanwal, MD, board certified dermatologist, told Medical News Today.

“(The study) fits a growing picture of psoriasis as both an immune and a metabolic disease, which matches what we see in clinic: our patients have higher rates of high cholesterol, obesity, diabetes and heart disease.”
—Christina Marcelus, MD

Understanding psoriasis: The vanin-pantethine metabolic axis

“Researchers discovered that Vanin enzymes can promote the activation of dendritic cells, which help initiate the inflammatory response, and influence pantheine metabolism and cholesterol accumulation in immune cell membranes,” Tanya Kormeili, MD, board certified dermatologist in Los Angeles, California, explained. “These enzymes appear to contribute to immune activation and dysregulation.”

Kormeili, who was not involved in the study, noted that this offers a unique and new approach to calming psoriasis without directly targeting interleukins, the signaling proteins blocked by many current biologics.

“Our traditional understanding of psoriasis is based on IL-23, IL-17, and TNF-alpha as markers of immune dysregulation,” Kormeili said. “The (vanin–pantethine) metabolic pathway itself is not entirely new, but it is newly identified as regulating immune activity in psoriasis. Changing cholesterol levels within dendritic cells to regulate inflammation is intriguing, and this study adds another important therapeutic pathway.”

For many dermatologists, the findings help explain a clinical pattern doctors have observed for years.

“What caught my attention was how closely cholesterol metabolism appeared to influence immune-cell activation,” said Kanwal. “Psoriasis has long been associated with metabolic conditions, but this study provides a possible biological explanation for part of that relationship.”

Calling the vanin–pantethine pathway’s role in regulating immune cells “an exciting discovery,” Mercy Odueyungbo-Jackson, MD, FAAD, FACMS, a board certified dermatologist and dermatology ambassador at Ezderm, pointed to the consistency of the trial results.

“What stood out most to me in the trials was how consistently panthethine reduced immune-cell activation,” Odueyungbo-Jackson said. “This research suggests that how immune cells process cholesterol may influence inflammation, potentially opening an entirely new avenue for psoriasis treatment.”

Although panthethine is a derivative of vitamin B5, it is structurally different. Pantethine directly converts to coenzyme A, which plays a key role in how the body processes fats and cholesterol.

Evidence so far has not shown the same effects from standard vitamin B5 supplements on the immune system or cholesterol.

“I would caution patients against assuming that taking vitamin B5 will improve their psoriasis. Researchers specifically studied pantethine, a derivative of vitamin B5, rather than the pantothenic acid or calcium pantothenate commonly found in supplements,” Odueyungbo-Jackson said.

“These forms cannot be assumed to have the same anti-inflammatory effects. This is promising research, not a reason to replace proven psoriasis treatments with supplements,” she added.

“Pantetheine is not a regular B5 vitamin supplement called pantothenic acid. Pantetheine is derived from B5 and has been studied for cholesterol regulation. We do not have evidence that B5 supplements create the same effect,” Kormeili chimed in.

What the study cannot say for sure yet

There were many limitations to this study, including the small sample size and short duration. Pantethine was also used as an add-on treatment and not as a replacement.

“The biggest limitation is the small human trial—just 24 patients followed for 12 weeks, without a reported placebo-controlled or blinded design,” Odueyungbo-Jackson said. She said that although the results were promising, larger trials were needed to determine safety and long-term effectiveness.

Kanwal agreed.

“Although the combination group improved more, this was a short, single-center study without a placebo comparison. Much of the mechanistic evidence also came from laboratory experiments and mouse models,” she said. “We need larger, longer clinical trials to establish effectiveness, safety, appropriate dosing and whether the benefits extend to patients with more severe psoriasis.”

Should I try panthethine if I have psoriasis?

Experts agree that patients should not stop their current therapies or try to self-treat based on this early-stage research and that larger clinical trials will have to confirm these benefits and clarify safety.

And although panthethine is generally tolerated well and considered safe at doses used in clinical trials, it can cause mild gastrointestinal symptoms like stomach upset. Separately, pantothenic acid can also interact with certain medications such as antibiotics.

“I would strongly discourage people from starting high-dose vitamin B5 supplements specifically for psoriasis based on these findings,” said Kanwal.

“The researchers used pantethine, a derivative of vitamin B5, rather than ordinary pantothenic acid or calcium pantothenate commonly found in supplements. These compounds are related but not interchangeable, and we cannot assume regular vitamin B5 produces the same effects.”
—Shamsa Kanwal, MD

“The authors themselves call it an early proof of concept. Twelve weeks tells us nothing about long-term benefit or safety, and we don’t know how panthethine would compare with, or combine with, the biologics and oral treatments many patients use for moderate to severe disease,” Marcelus said.

Marcelus also pointed out that the supplement seemed to benefit a specific group, in particular.

“What stood out to me is that the benefit in the small patient trial seemed concentrated in people with high cholesterol at baseline,” she said. “If that holds up, it hints that a metabolic approach might help a specific subgroup of patients rather than everyone with psoriasis.”

“I also found the preliminary human results encouraging, particularly among patients with abnormal cholesterol levels. However, I would not interpret these findings as evidence that a vitamin supplement can replace established psoriasis treatments,” Kanwal concluded.